Our History

ExpreS2ion Biotechnologies ApS was founded in 2010, based on a decade-long research on developing an optimised protein expression system using Drosophila S2 cells. We call it the ExpreS2 platform. From over 20 years of using ExpreS2, the platform’s superiority to alternative systems when it came to the expression of complex proteins is well-documented.
In 2016, ExpreS2ion Biotech Holding AB was founded and listed on Nasdaq First North Stockholm, and in 2017 the joint venture company AdaptVac was established. AdaptVac has developed a capsid Virus-Like Particle (cVLP) platform that makes it possible to create next-generation vaccines and vaccine-like treatments, and it is thus perfect match for our ExpreS2 development and manufacturing platform.

Going forward, we are increasing our focus on advancing ExpreS2ion’s growing product development pipeline together with industrial and academic partners, while continuing to offer attractive discovery, development, and manufacturing services based on our platform and know-how.

Selected company events


ExpreS2ion Biotechnologies ApS is founded.


The company receives an HTF grant worth 3.5 MDKK together with University of Copenhagen and CMC Biologics for malaria research.


Jenner Institute at the University of Oxford receives MRC and EVI contributions for preclinical RH5 malaria vaccine, developed on the ExpreS2 platform together with ExpreS2ion.


The first GMP (Good Manufacturing Practice) production batch of ExpreS2-produced proteins for malaria phase 1 clinical studies is manufactured.


A multi-year research license is signed with the global pharmaceutical company Roche.


A scientific article, co-authored by ExpreS2ion researchers, is published in the renowned journal Nature.  


Approval for a clinical phase Ia study in Germany for the pregnancy-associated malaria vaccine project.


The ExpreS2ion share is listed on Nasdaq First North Growth Market in Stockholm, Sweden.


The Joint Venture AdaptVac is established, enabling the use of the ground-breaking Virus-Like Particle (VLP) technology to create next-generation vaccines and vaccine-like treatments in ExpreS2ion’s projects.


A CRISPR-Cas technology license is obtained, enabling substantially improved gene-editing capabilities.


HighMan-S2, a new glyco-engineered cell line under the GlycoX-S2™ platform, becomes commercially available.


A ExpreS2-produced Zika Ns1 antigen becomes available from Virion/Serion.


ExpreS2ion signs an option to exclusively license AdaptVac’s AV001 breast cancer vaccine.


The company and AdaptVac initiates a partly EU Horizon 2020-funded cVLP COVID-19 vaccine program together with the PREVENT-nCoV European consortium.


The international next-generation influenza vaccine consortium INDIGO, with ExpreS2ion as a participating member, receives a 10 MEUR Horizon 2020 grant of which the company receives 0.6 MEUR directly.


ExpreS2ion announces successful proof of concept in animals for the cVLP COVID-19 vaccine.